Keratoconus is a chronic progressive non - inflammatory disorder characterised by progressive steepening and thinning of cornea and high myopic astigmatism, accounting for poor visual acuity in such individuals. Keratoconus seems to be more advanced on presentation, in young patients. The investigators intend to evaluate the effectiveness of conventional collagen cross linking in young patients diagnosed with keratoconus.
Keratoconus is progressive ectatic corneal disorder characterised by progressive corneal thinning, steep corneal curvatures and usually associated with high irregular myopic astigmatism. The major problems concerning keratoconus in young patients are; 1. Rapid rates of progression in young keratoconic corneas as compared to adults. 2. Poor biomechanical properties of young corneas. 3. Poor quality of vision, which predisposes to a very poor quality of life. 4. High rates of complications and failure post keratoplasty in young patients. The investigators intend to evaluate the effectiveness of conventional collagen crosslinking in young patients with keratoconus with regards to keratometric indices and visual acuity.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
Vasan Eye Care Hospital
Chennai, Tamil Nadu, India
Change in Keratometric indices
The keratometric readings in the steepest and flattest meridians, along with the average K readings were compared pre and post treatment using conventional collagen cross linking technique at 1 month post cross linking.
Time frame: 1 months
Improvement in vision
Comparison of visual rehabilitation was done as improvements noted in Snellen line numbers and best corrected visual acuity (B.C.V.A) converted to decimals, pre and post treatment at 1,3,6,12 months post treatment.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.